Chemiluminescence assay of in vivo inflammation
First Claim
1. A method of evaluating the in vivo state of inflammation of a patient, comprising:
- a) determining the extent of opsonin receptor expression on phagocytes in a first portion of a phagocyte-containing biological sample of a patient,b) contacting a second portion of the biological sample with receptor expression priming agent to obtain maximal expression of opsonin receptors on phagocytes in the second portion of the biological sample;
c) determining the extend of opsonin receptor expression on phagocytes in the second portion of the sample; and
thend) comparing the extent of opsonin receptor expression on the phagocytes of the first and second portions of the sample as a measure of the in vivo state of inflammation of the patient.
2 Assignments
0 Petitions
Accused Products
Abstract
The presence or amount of in vivo inflammation of a patient is determined by comparing the extent of opsonin receptor expression in vivo on phagocytes of a patient with the maximum opsonin receptor expression inducible on phagocytes of the patient in vitro after stimulation with a receptor expression priming agent. Preferably, the in vivo state of inflammation of a patient is determined by contacting a first portion of a phagocyte containing biological sample from the patient with a opsonified oxidative metabolism stimulating agent capable of elicting metabolic activation and with a chemiluminigenic substrate, contacting a second portion of the biological sample from the patient with an opsonin receptor expression priming agent, an opsonfield oxidative metabolism stimulating agent capable of eliciting metabolic activation and a chemiluminigenic substrate, and then comparing the chemiluminescence response of the first and second portions of the sample as a measure of the immune response potential or state of inflammation of the patient. Phagocyte function is additionally quantitatively evaluated by measuring the phagocyte oxygenation capacity of a maximally opsonin receptor primed and stimulated biological sample of a patient, determining the specific oxygenation capacity per phagocyte in the sample, and comparing the specific oxygenation capacity to a set of controls representing the normal distribution of specific oxygenation established from testing a large population. The phagocyte-specific oxygenation capacity is determined by contacting the sample with an opsonin receptor expression priming agent, an opsonified oxidative metabolism stimulating agent and a chemiluminigenic substrate, measuring the chemiluminescence response of the sample, determining the chemiluminescence response per phagocyte of the sample and comparing the response per phagocyte with that of the normal range of values. Kits and reagents are provided for use in the practice of the disclosed methods.
-
Citations
60 Claims
-
1. A method of evaluating the in vivo state of inflammation of a patient, comprising:
-
a) determining the extent of opsonin receptor expression on phagocytes in a first portion of a phagocyte-containing biological sample of a patient, b) contacting a second portion of the biological sample with receptor expression priming agent to obtain maximal expression of opsonin receptors on phagocytes in the second portion of the biological sample; c) determining the extend of opsonin receptor expression on phagocytes in the second portion of the sample; and
thend) comparing the extent of opsonin receptor expression on the phagocytes of the first and second portions of the sample as a measure of the in vivo state of inflammation of the patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method of evaluating the systemic immune reserve of a patient, comprising:
-
a) contacting a first portion of a phagocyte-containing biological sample from the patient with an opsonified oxidative metabolism stimulating agent and a chemiluminigenic substrate; b) contacting a second portion of the sample with a receptor expression priming agent, an opsonified oxidative metabolism stimulating agent and a chemiluminigenic substrate; c) measuring the chemiluminescence responses of the first and second portions of the sample; and d) comparing the chemiluminescence responses of the first and second portions of the sample as an indication of the systemic immune reserve of the patient. - View Dependent Claims (19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)
-
-
32. A method of evaluating the humoral-immune modulated specific activity of phagocytes in a phagocyte-containing biological sample of a patient, comprising:
-
a) contacting the sample with a receptor expression priming agent, an opsonified oxidative metabolism stimulating agent and a chemiluminigenic substrate, b) measuring the chemiluminescence response of the sample, c) determining the approximate number of phagocytes in the sample; d) determining the specific chemiluminescence response per phagocyte in the sample as a measure of phagocyte specific activity; and d) comparing the phagocyte specific activity with those of a range of controls. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)
-
-
46. A kit for use in the evaluation of the in vivo state of inflammation of a patient or the humoral-immune modulated specific activity of phagocytes comprising:
-
a) an opsonin receptor expression priming agent in an amount sufficient to obtain maximal expression of opsonin receptors on said phagocytes but not so high as to result in direct, opsonin receptor-independent oxidative activity; b) an opsonified oxidative metabolism stimulating agent; and c) a chemiluminigenic substrate. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)
-
Specification